<![CDATA[Real-World Tislelizumab Combo Shows Encouraging Efficacy in ES-SCLC]]>

Data ReadoutpositivetislelizumabPositive

AI Analysis

Summary

Real-world data demonstrated that tislelizumab combined with chemotherapy and radiotherapy showed encouraging efficacy and prolonged progression-free survival in extensive-stage small cell lung cancer patients.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Real-world data showed tislelizumab in combination with chemotherapy and radiotherapy demonstrated encouraging efficacy and prolonged progression-free survival in ES-SCLC patients

Importance:6/10

Sentiment:

0.70

real-world evidenceoncologyimmunotherapySCLCcombination therapyradiotherapy

Related Companies

$WHEN

Read the original article

Published by Cancer Network on September 21, 2026 8:00 PM

Read Original